- Current report filing (8-K)
January 05 2009 - 5:00PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
December
30, 2008
Date
of Report (Date of earliest event reported)
PRO-PHARMACEUTICALS,
INC.
(Exact
Name of Registrant as Specified in Charter)
Nevada
|
000-32877
|
04-3562325
|
(State
or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer
Identification
No.)
|
7 WELLS AVENUE
NEWTON, MASSACHUSETTS
02459
|
(Address
of Principal Executive Offices)
(Zip
code)
|
(617) 559-0033
(Registrant’s telephone number, including
area code)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions
(
see
General Instruction
A.2. below)
:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Change in Directors or Principal Officers, Financial Statements and
Exhibits
Item
5.02 Departure of Directors or Principal Officers; Election of
Directors; Appointment of Principal Officers.
On December 31
st
, 2008, Pro-Pharmaceuticals, Inc. (“the
Company”) announced that Theodore H. Zucconi, Ph.D., had been terminated
as President. Dr. Zucconi continues as a member of the Company’s Board
of Directors.
Item
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing
Rule or Standard; Transfer of Listing.
On December 23, 2008, the Company met with the NYSE Alternext US (“the
Exchange”) to appeal the Exchange’s decision to begin the de-listing
process of the company’s common stock. The Company is out-of-compliance
with Section 1003(a)(ii) of the Exchange’s Company Guide. On December
30, 2008, the Exchange notified the Company that it has denied the
Company’s appeal and will begin the de-listing process in accordance
with Exchange rules. The Company anticipates that its shares will be
listed for quotation on the Over-the-Counter Bulletin Board (OTCBB) or
another market and has begun the OTCBB listing process. The Company
will notify investors of its new stock symbol as soon as it becomes
available.
Item
9.01 Financial Statements and Exhibits.
|
(d) Exhibits.
|
|
News Release of Pro-Pharmaceuticals, Inc., dated December 31, 2008.
|
SIGNATURES
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
|
PRO-PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/ David Platt
|
|
|
|
David Platt
|
|
|
|
Chief Executive Officer
|
|
|
|
|
Date:
|
January 5, 2009
|
|
|
EXHIBIT INDEX
Exhibit
Number
|
|
Exhibit
|
99.1
|
|
News Release of Pro-Pharmaceuticals, Inc., dated December 31, 2008.
|
Pro (AMEX:PRW)
Historical Stock Chart
From Apr 2024 to May 2024
Pro (AMEX:PRW)
Historical Stock Chart
From May 2023 to May 2024